GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » Issuance of Debt

Gongwin Biopharm Holdings Co (ROCO:6617) Issuance of Debt : NT$120.97 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Gongwin Biopharm Holdings Co Issuance of Debt?

Gongwin Biopharm Holdings Co's Issuance of Debt for the three months ended in Mar. 2024 was NT$6.51 Mil.

Gongwin Biopharm Holdings Co's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 was NT$120.97 Mil.

Gongwin Biopharm Holdings Co Issuance of Debt Historical Data

The historical data trend for Gongwin Biopharm Holdings Co's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gongwin Biopharm Holdings Co Issuance of Debt Chart

Gongwin Biopharm Holdings Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 228.03 8.38 144.56 50.29 119.16

Gongwin Biopharm Holdings Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 7.70 14.12 92.64 6.51

Gongwin Biopharm Holdings Co Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$120.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gongwin Biopharm Holdings Co Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Gongwin Biopharm Holdings Co's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gongwin Biopharm Holdings Co (ROCO:6617) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gongwin Biopharm Holdings Co Ltd (ROCO:6617) » Definitions » Issuance of Debt
Comparable Companies
ROCO:4147 ROCO:4174 ROCO:6976 ROCO:6919 ROCO:6547 ROCO:4162 ROCO:6712 ROCO:6586 TPE:4142 ROCO:4728 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Website
http://www.gongwinbiopharm.com
Gongwin Biopharm Holdings Co Ltd is a Taiwanese biotech and pharmaceutical company engaged in research and development of anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma.

Gongwin Biopharm Holdings Co (ROCO:6617) Headlines

No Headlines